Strategies for Tissue Engineering Cardiac Constructs to Affect Functional Repair Following Myocardial Infarction

Article

DOI: 10.1007/s12265-011-9303-1

Cite this article as:
Ye, K.Y. & Black, L.D. J. of Cardiovasc. Trans. Res. (2011) 4: 575. doi:10.1007/s12265-011-9303-1

Abstract

Tissue-engineered cardiac constructs are a high potential therapy for treating myocardial infarction. These therapies have the ability to regenerate or recreate functional myocardium following the infarction, restoring some of the lost function of the heart and thereby preventing congestive heart failure. Three key factors to consider when developing engineered myocardial tissue include the cell source, the choice of scaffold, and the use of biomimetic culture conditions. This review details the various biomaterials and scaffold types that have been used to generate engineered myocardial tissues as well as a number of different methods used for the fabrication and culture of these constructs. Specific bioreactor design considerations for creating myocardial tissue equivalents in vitro, such as oxygen and nutrient delivery as well as physical stimulation, are also discussed. Lastly, a brief overview of some of the in vivo studies that have been conducted to date and their assessment of the functional benefit in repairing the injured heart with engineered myocardial tissue is provided.

Keywords

Tissue engineering Myocardial infarction Biomaterials Bioreactor Heart failure Polymer scaffolds 

Abbreviations

MI

Myocardial infarction

ECM

Extracellular matrix

FDA

US Food and Drug Administration

SIS

Small intestinal submucosa

UBM

Urinary bladder matrix

GAGs

Glycosaminoglycans

PLGA

Poly(lactic-co-glycolic acid)

PNIPAAm

Poly(N-isopropylacrylamide)

PTMCLA

Poly(trimethylene carbonate-co-lactide)

VEGF

Vascular endothelial growth factor

PEG

Polyethylene glycol

FAK

Focal adhesion Kinase

RhoA

Ras homolog gene family, member A

AVL

Arteriovenous blood vessel loop

FS

Fractional shortening

LVEF

Left ventricular ejection fraction

EHTs

Engineered heart tissue

LVEDD

Left ventricular end-diastolic dimension

LVEDV

Left ventricular end-diastolic volume

bFGF

Basic fibroblast growth factor

CPCs

Cardiac progenitor cells

IGF-1

Insulin-like growth factor 1

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Biomedical EngineeringTufts UniversityMedfordUSA

Personalised recommendations